ACD: Diabetes and Weight Management Part 2-Pharmacological Agents for Diabetes and Obesity Infographic

Pharmacological Agents for Diabetes and Obesity Infographic

Pdf Summary

The provided infographic, synthesized from the American Diabetes Association's (ADA) 2023 Standards of Care, offers a visual guide on pharmacologic agents for diabetes and obesity management. Key highlights include the benefits of incretins in type 2 diabetes management, particularly for delaying diabetes progression, improving glycemia, reducing the need for glucose-lowering medications, and aiding in sustained diabetes remission for at least two years. Incretins also help achieve and maintain meaningful weight loss, thus reducing obesity-associated health risks.<br /><br />The infographic categorizes treatment options according to BMI, recommending intensive behavioral counseling, obesity pharmacotherapy, and bariatric surgery based on BMI cut points, with specific recommendations for Asian American individuals. When choosing glucose-lowering medications for type 2 diabetes patients who are overweight or obese, weight considerations are crucial. The infographic advises minimizing medications associated with weight gain and utilizing obesity pharmacotherapy as an adjunct to lifestyle changes for selected individuals with a BMI of 27 kg/m² or higher.<br /><br />The guide emphasizes evaluating the effectiveness of obesity pharmacotherapy, defined as a 5% weight loss after three months, and advises reevaluating treatment approaches if this target is not met or if safety concerns arise. <br /><br />The efficacy of glucose-lowering medications for weight loss is categorized as follows:<br />- **Very High**: Medications like Semaglutide (SC or PO) and Tirzepatide.<br />- **High**: Exenatide, Liraglutide, Dulaglutide.<br />- **Intermediate**: SGLT2 inhibitors (Sodium–glucose cotransporter 2 inhibitors).<br />- **Neutral**: Includes metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), among others.<br /><br />For further information on incretins and weight management for type 2 diabetes, contact the ADA at 1-800-DIABETES or visit their website at diabetes.org.

Keywords

ADA 2023 Standards

diabetes management

obesity management

incretins

glucose-lowering medications

obesity pharmacotherapy

bariatric surgery

weight loss

type 2 diabetes

BMI recommendations